[Tumor markers in cervical carcinoma]. / Marcadores tumorales en el carcinoma de cérvix.

The value of seven tumor markers to differentiate preinvasive and invasive gynecologic tumors is studied. CEA beta -hCH. alpha -FP and alpha-glycoprotein/prealbumin quotient allow such differentiation, while TPA, LDH-V and PRL have no value as markers of the gynecologic tumors and to not distinguish between preinvasive and invasive tumors.

[Our experience in the surgical treatment of cervical carcinoma]. / Nuestra experiencia en el tratamiento quirúrgico del carcinoma de cérvix.

The authors study 60 cases of invasive carcinoma of the cervix uteri belonging to several tumor stages. They analyze their past history, histology, lymph node invasion and symptomatology. The authors indicate the employed therapy and the five year survival rate, that was 82.3% for stage Ib tumors, 0% for stage IIA and 78.7% for stage IIB. The data for stage IIA are not significant statistically because the small number of the studied cases.

[Chemotherapy of advanced cervical carcinoma]. / Quimioterapia del carcinoma de cérvix avanzado.

The authors describe a therapeutic trial of advanced cervical carcinoma using adriamycin and Methotrexate (84 cases), cis-platinum (9 cases), bleomycin and mitomycin C (18 cases), and a combination of cis-platinum, bleomycin and mitomycin C. Good results were never obtained.